BTIG Initiates Carisma Therapeutics(CARM.US) With Hold Rating
D. Boral Capital Initiates Carisma Therapeutics(CARM.US) With Buy Rating, Announces Target Price $1
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), BioCardia (BCDA) and Guardian Pharmacy Services, Inc. Class A (GRDN)
Carisma Therapeutics Price Target Cut to $1.00/Share From $12.00 by D. Boral Capital
CARISMA Therapeutics Analyst Ratings
D. Boral Capital Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $1
BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating
H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
CARISMA Therapeutics Analyst Ratings
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating
Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects
Carisma Therapeutics Cut to In-Line From Outperform by Evercore ISI Group
Carisma Therapeutics Price Target Cut to $0.70/Share From $4.00 by Evercore ISI Group
Evercore Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $0.7
Carisma Therapeutics Cut to Neutral From Buy by BTIG
BTIG Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
BTIG Downgrades Carisma Therapeutics (CARM) to a Hold
CARISMA Therapeutics Analyst Ratings